GSK3B and supranuclear palsy, progressive, 1: According to the molecular docking data, tideglusib, which is designed for the treatment of AD [42] and progressive supranuclear palsy (PSP), bound irreversibly to the non-ATP-competitive GSK-3β site [43] (Figure 7).